Trial Profile
Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 May 2022
Price :
$35
*
At a glance
- Drugs Erythropoietin (Primary)
- Indications Anaemia
- Focus Pharmacodynamics
- Acronyms NIMBUS
- 17 May 2022 Results published in the Stroke
- 17 Aug 2020 Status changed to completed.
- 04 Feb 2016 New trial record